Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.4.1657

Plasma Nuclear Factor Kappa B and Serum Peroxiredoxin 3 in Early Diagnosis of Hepatocellular Carcinoma  

Ismail, Saber (Department of Tropical Medicine & Infectious Diseases, Faculty of Medicine, Tanta University)
Mayah, Wael (Department of Tropical Medicine & Infectious Diseases, Faculty of Medicine, Tanta University)
Battia, Hassan El (Department of Tropical Medicine & infectious Diseases, Faculty of Medicine, Kafrelsheikh University)
Gaballah, Hanaa (Department of Medical Biochemistry, Faculty of Medicine, Tanta University)
Jiman-Fatani, Asif (Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University)
Hamouda, Hala (Department of Medical Biochemistry, Faculty of Medicine, Tanta University)
Afifi, Mohamed A. (Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University)
Elmashad, Nehal (Department of Clinical Oncology, Faculty of Medicine, Tanta University)
Saadany, Sherif El (Department of Tropical Medicine & Infectious Diseases, Faculty of Medicine, Tanta University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.4, 2015 , pp. 1657-1663 More about this Journal
Abstract
Background: Early diagnosis of hepatocellular carcinoma (HCC) is the most important step in successful treatment. However, it is usually rare due to the lack of a highly sensitive specific biomarker so that the HCC is usually fatal within few months after diagnosis. The aim of this work was to study the role of plasma nuclear factor kappa B (NF-${\kappa}B$) and serum peroxiredoxin 3 (PRDX3) as diagnostic biomarkers for early detection of HCC in a high-risk population. Materials and Methods: Plasma nuclear factor kappa B level (NF-${\kappa}B$) and serum peroxiredoxin 3 (PRDX3) levels were measured using enzyme linked immunosorbent assay (ELISA), in addition to alpha-fetoprotein (AFP) in 72 cirrhotic patients, 64 patients with HCC and 29 healthy controls. Results: NF-${\kappa}B$ and PRDX3 were significantly elevated in the HCC group in relation to the others. Higher area under curve (AUC) of 0.854 (for PRDX3) and 0.825 (for NF-${\kappa}B$) with sensitivity of 86.3% and 84.4% and specificity of 75.8% and 75.4% respectively, were found compared to AUC of alpha-fetoprotein (AFP) (0.65) with sensitivity of 72.4% and specificity of 64.3%. Conclusions: NF-${\kappa}B$ and PRDX3 may serve as early and sensitive biomarkers for early detection of HCC facilitating improved management. The role of nuclear factor kappa B (NF-${\kappa}B$) as a target for treatment of liver fibrosis and HCC must be widely evaluated.
Keywords
Nuclear factor kappa B; peroxiredoxin 3; hepatocellular carcinoma; early diagnosis;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Altekruse SF, McGlynn KA, Reichman ME (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 27, 1485-91.   DOI
2 Arsura M, Cavin LG (2005). Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett, 229, 157-69.   DOI
3 Basu A, Banerjee H, Rojas H, et al (2011). Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate, 71, 755-65.   DOI
4 Beale G, Chattopadhyay D, Gray J, et al (2008). AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer, 8, 200-8.   DOI
5 Bonacchi A, Petrai I, Defranco RM, et al (2003). The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology, 125, 1060-76.   DOI
6 Nonn L, Berggren M, Powis G (2003). Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res, 1, 682-9.
7 Poon D, Anderson BO, Chen LT, et al (2009). Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit. Lancet Oncol, 10, 1111-8.   DOI
8 Punsawad C, Krudsood S, Maneerat Y, et al (2012). Activation of nuclear factor kappa B in peripheral blood mononuclear cells from malaria patients. Malar J, 11, 191.   DOI
9 Qiao B, Wang J, Xie J, et al (2012). Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach. Int J Mol Med, 29, 832-40.
10 Rabilloud T, Heller M, Gasnier F, et al (2002). Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem, 277, 19396-401.   DOI
11 Schwabe RF, Seki E, Brenner DA (2006). Toll-like receptor signaling in the liver. Gastroenterology, 130, 1886-900.   DOI
12 Seki E, De Minicis S, Osterreicher CH, et al (2007). TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med, 13, 1324-32.   DOI   ScienceOn
13 Shi L, Wu LL, Yang JR, et al (2014). Serum peroxiredoxin3 is a useful biomarker for early diagnosis and assessment of prognosis of hepatocellular carcinoma in Chinese patients. Asian Pac J Cancer Prev, 15, 2979-86   DOI
14 Sunami Y, Leithauser F, Gul S, et al (2012). Hepatic activation of IKK/NF${\kappa}B$ signaling induces liver fibrosis via macrophagemediated chronic inflammation. Hepatology, 56, 1117-28.   DOI   ScienceOn
15 Cabibbo G, Craxi A (2101). Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci, 14, 352-5.
16 Bosch FX, Ribes J, Diaz M, Cleries R (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127, 5-16.   DOI
17 Bouchard MJ, Navas-Martin S (2011). Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett, 305, 123-43.   DOI   ScienceOn
18 Bruix J, Sherman M (2005). Practice guidelines committee, American association for the study of liver diseases. management of hepatocellular carcinoma. Hepatology, 42, 1208-36.   DOI
19 Chan HL, Tsang SW, Leung NW, et al (2002). Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol, 97, 1211-5.   DOI
20 Dietz KJ, Horling F, Konig J, Baier M (2002). The function of oroplast 2-cysteine peroxiredoxin in peroxide detoxification and its regulation. J Exp Bot, 53, 1321-9.   DOI
21 Dominguez I, Sonenshein GE, Seldin DC (2009). Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NFkappaB signaling: linking development and cancer. Cell Mol Life Sci, 66, 1850-7.   DOI
22 Gaballah HH, Zakaria SS, Ismail SA (2014). Activity and expression pattern of NF-${\kappa}B$ /P65 in peripheral blood from hepatocellular carcinoma patients - link to hypoxia inducible factor-$1{\alpha}$. Asian Pac J Cancer Prev, 15, 6911-7.   DOI
23 Gomaa AJ, Khan SA, Leen EL, Waked I, Taylor-Robinson SD (2009). Diagnosis of hepatocellular carcinoma. World J Gastroenterol, 15, 1301-14.   DOI
24 Trachootham D, Alexandre J, Huang P (2009). Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov, 8, 579-91.   DOI
25 Tai DI, Tsai SL, Chen YM, et al (2000). Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology, 31, 656-64.   DOI
26 Teofanescu I, Gologan E, Stefanescu E, Balan G (2010). Surveillance of cirrhosis for hepatocellular carcinoma--clinical validation of new serological biomarkers for improved diagnosis. Rev Med Chir Soc Med Nat Iasi, 114, 39-46.
27 Thomas M, Zhu A (2005). Hepatocellular carcinoma: the need for progress. J Clin Oncol, 23, 2892-9.   DOI
28 Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA (2011). Level of ${\alpha}$-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol, 9, 989-94.   DOI
29 Wilkins T, Malcolm JK, Raina D, Schade RR (2010). Hepatitis C: diagnosis and treatment. Am Fam Physician, 81, 1351-7.
30 Wonsey DR, Zeller KI, Dang CV (2002). The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci U S A, 99, 6649-54.   DOI
31 Wu W, Yao DF, Qiu LW, et al (2009). Characteristics of hepatic nuclear-transcription factor-kappa B expression and quantitative analysis in rat hepatocarcinogenesis. Hepatobiliary Pancreat Dis Int, 8, 504-9.
32 Wu XY, Fu ZX, Wang XH (2010). Peroxiredoxins in colorectal neoplasms. Histol Histopathol, 25, 1297-303.
33 Huh JY, Kim Y, Jeong J, et al (2012). Peroxiredoxin 3 is a key molecule regulating adipocyte oxidative stress, mitochondrial biogenesis, and adipokine expression. Antioxid Redox Signal, 16, 229-43.   DOI
34 Guo J, Loke J, Zheng F, et al (2009). Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology, 49, 960-8.   DOI
35 Haruki K, Shiba H, Fujiwara Y, et al (2013). Inhibition of nuclear factor-${\kappa}B$ enhances the antitumor effect of tumor necrosis factor-${\alpha}$ gene therapy for hepatocellular carcinoma in mice. Surgery, 154, 468-78.   DOI
36 Huang HC, Zheng S, VanBuren V, Zhao Z (2010). Discovering disease-specific biomarker genes for cancer diagnosis and prognosis. Technol Cancer Res Treat, 9, 219-30.   DOI
37 Hung CH, Lee CM, Kuo FY, et al (2008). Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor-kappaB in chronic hepatitis C. Liver Int, 28, 339-46.   DOI
38 Iakova P, Timchenko L, Timchenko NA (2011). Intracellular signaling and hepatocellular carcinoma. Semin Cancer Biol, 21, 28-34.
39 Jo M, Nishikawa T, Nakajima T, et al (2011). Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. J Gastroenterol, 46, 809-21.   DOI
40 Kim K, Yu M, Han S et al (2009). Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep, 21, 1391-6.
41 Li XQ, Zhang SL, Cai Z, et al (2009). Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma. Cancer Lett, 275, 109-16.   DOI
42 Yu SC, Yeung DT, So NM (2004). Imaging features of hepatocellular carcinoma. Clin Radiol, 59, 145-56.   DOI
43 Yamamoto K, Imamura H, Matsuyama Y, et al (2010). AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol, 45, 1272-82.   DOI
44 Yokoo H, Yasuda J, Nakanishi K, et al (2011). Clinicopathological significance of nuclear factor-${\kappa}B$ activation in hepatocellular carcinoma. Hepatol Res, 41, 240-9.   DOI
45 Youns MM, Abdel Wahab AH, Hassan ZA, Attia MS (2013). Serum talin-1 is a potential novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients. Asian Pac J Cancer Prev, 14, 3819-23.   DOI   ScienceOn
46 Zekri Ael-R, Nassar AA, El-Din El-Rouby MN, et al (2013). Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac J Cancer Prev, 14, 6721-6.   DOI   ScienceOn
47 Zhang F, Wang Q, Ye L, Feng Y, Zhang X (2010). Hepatitis B virus X protein upregulates expression of calpain small subunit 1 via nuclear factor-kappaB/p65 in hepatoma cells. J Med Virol, 82, 920-8.   DOI
48 Zhang ZM, Zhang YM, Gao S, et al (2014). Treatment efficacy and prognostic factors for huge HCC based on Barcelona clinic liver cancer staging. Asian Pac J Cancer Prev, 15, 8823-8.   DOI
49 Luedde T, Schwabe RF (2011). NF-${\kappa}B$ in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 8, 108-18.   DOI   ScienceOn
50 Liu X, Feng R, Du L (2010). The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett, 584, 3185-92.   DOI
51 Macias Rodriguez MA, Rendon Unceta P, Tejada Cabrera M, et al (2000). Risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Rev Esp Enferm Dig, 92, 458-69.
52 Makuuchi M, Kokudo N, Arii S, et al (2008). Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res, 38, 37-51.   DOI
53 Marra M, Sordelli IM, Lombardi A, et al (2011). Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med, 10, 9:171.
54 Mendy M, Walton R (2009). Molecular pathogenesis and early detection of hepatocellular carcinoma-perspectives from West Africa. Cancer Lett, 286, 44-51.   DOI   ScienceOn
55 Miura K, Kodama Y, Inokuchi S, et al (2010). Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology, 139, 323-34.   DOI
56 Nagaoka S, Yatsuhashi H, Hamada H, et al (2003). The desgamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer, 98, 2671-7.   DOI
57 Naugler WE, Karin M (2008). NF-kappa B and canceridentifying targets and mechanisms. Curr Opin Genet Dev, 18, 19-26.   DOI   ScienceOn